Dorzagliatin (HMS5552), a novel dual‐acting glucokinase activator, improves glycaemic control and pancreatic β‐cell function in patients with type 2 diabetes: A 28‐day treatment study using biomarker‐guided patient selection
Authors:
- 29 April 2018
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (9) , 2113-2120
Abstract
Aims: To investigate the pharmacokinetics and pharmacodynamics of a dual‐acting glucokinase activator, dorzagliatin, and its safety, tolerability and effect on pancreatic β‐cell function in Chinese patients with type 2 diabetes (T2D). Materials and methods: A total of 24 T2D patients were selected, utilizing a set of predefined clinical biomarkers, and were randomized to receive dorzagliatin 75 mg twice or once daily (BID, QD respectively) for 28 days. Changes in HbA1c and glycaemic parameters from baseline to Day 28 were assessed. In addition, changes in β‐cell function from baseline to Day 32 were evaluated. Results: Significant reductions in HbA1c were observed in both regimens on Day 28 (−0.79%, 75 mg BID; −1.22%, 75 mg QD). Similar trends were found in the following parameters, including reductions from baseline in fasting plasma glucose by 1.20 mmol/L and 1.51 mmol/L, in 2‐hour postprandial glucose by 2.48 mmol/L and 5.03 mmol/L, and in glucose AUC 0–24 by 18.59% and 20.98%, for the BID and QD groups, respectively. Both regimens resulted in improvement in β‐cell function as measured by steady state HOMA 2 parameter, %B, which increased by 36.31% and 40.59%, and by dynamic state parameter, ΔC 30 /ΔG 30 , which increased by 24.66% and 167.67%, for the BID and QD groups, respectively. Dorzagliatin was well tolerated in both regimens, with good pharmacokinetic profiles. Conclusions: Dorzagliatin treatment for 28 days in Chinese T2D patients, selected according to predefined biomarkers, resulted in significant improvement in β‐cell function and glycaemic control. The safety and pharmacokinetic profile of dorzagliatin supports a subsequent Phase II trial design and continued clinical development.Keywords
Funding Information
- National Major Scientific and Technological Special Project for ‘Significant New Drugs Development’ (2014ZX09101002004, 2014ZX09303303)
- Shanghai Science and Technology Innovation Action Project (14431908300, 15XD1520500)
- Shanghai Innovation Fund for Small and Medium-Sized Technology-Based Firms (1402H281800)
This publication has 27 references indexed in Scilit:
- GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?Trends in Pharmacological Sciences, 2013
- Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clampInt. Journal of Clinical Pharmacology and Therapeutics, 2012
- Discovery of Piragliatin—First Glucokinase Activator Studied in Type 2 Diabetic PatientsJournal of Medicinal Chemistry, 2012
- Assessment of β-cell function in human patientsIslets, 2012
- Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy DogsMolecular Pharmacology, 2011
- Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 DiabetesDiabetes Care, 2011
- Glucokinase Activators for Diabetes TherapyDiabetes Care, 2011
- Assessing the potential of glucokinase activators in diabetes therapyNature Reviews Drug Discovery, 2009
- Glucokinase and glucose homeostasis: proven concepts and new ideasBiochemical Society Transactions, 2005
- Use and Abuse of HOMA ModelingDiabetes Care, 2004